Suchergebnisse - "Lee, Holly"

PubPharm (55)

1

Artificial Intelligence Individualized Risk Classifier in Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Neri, P. | Lee, H. | Bahlis, N.

2

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma : efficacy, safety, and resistance mechanisms

enthalten in: Blood | 2024

von Lee, H. | Neri, P. | Bahlis, N.

3

Cereblon-Targeting Ligase Degraders in Myeloma : Mechanisms of Action and Resistance

enthalten in: Hematology/oncology clinics of North America | 2024

von Lee, H. | Neri, P. | Bahlis, N.

4

Daratumumab for the treatment of relapsed/refractory AL amyloidosis : experience from the amyloidosis Program of Calgary (APC)

enthalten in: Leukemia & lymphoma | 2024

von Levin, D. | Lewis, E. | McCulloch, S. | +6

5

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma

enthalten in: Blood cancer discovery | 2024

von Neri, P. | Barwick, B. | Jung, D. | +18

CommentIn: Blood Cancer Discov. 2024 Jan 8;5(1):5-7. - PMID 38085608

6

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

enthalten in: Blood | 2024

von Leblay, N. | Ahn, S. | Tilmont, R. | +11

CommentIn: Blood. 2024 Jan 4;143(1):4-5. - PMID 38175678

7

Current use of bispecific antibodies to treat multiple myeloma

enthalten in: Hematology. American Society of Hematology. Education Program | 2023

von Lee, H. | Neri, P. | Bahlis, N.

8

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

enthalten in: Cancer cell | 2023

von Friedrich, M. | Neri, P. | Kehl, N. | +17

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):505-506. - PMID 37173587

9

Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR) : Analysis Using the iStopMM Criteria

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Lewis, E. | Lee, H. | Fine, N. | +6

10

Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Nie, C. | Lee, H. | Tay, J. | +5

1
2
3
4
5
6
Nächster »
[6]